December 10, 2024, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Vivos Therapeutics, Inc. (NASDAQ: VVOS) titled, “New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind.” The report can be accessed here.

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including obstructive sleep apnea (“OSA”) in adults and children, reported that the American Medical Association (“AMA”) has issued new CPT(R)medical codes that are applicable to Vivos CARE oral medical devices; the codes are effective beginning Jan. 1, 2025.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults), has entered into definitive purchase agreements with institutional investors. Under these agreements, Vivos will issue and sell an aggregate of 1,363,812 shares of its common stock at a purchase price of $3.15 per unit in a registered direct offering.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (“SRBDs”) including obstructive sleep apnea (“OSA”) has received breakthrough clearance from the U.S. Food and Drug Administration (“FDA”). According to the announcement, the company has received approval to use its Vivos proprietary oral medical device to treat moderate to severe OSA and snoring in children; the company believes this is the first time the FDA has given 510(k) clearance for this type of treatment for children aged 6 to 17 years of age.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is one of today’s top gainers. The company’s shares have moved 324.17% on the day to $ 18.62 .

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting the financial results and operating highlights for its second quarter 2024 and six-month period, which ended June 30, 2024. Highlights of the report include a 19% increase in revenue both sequentially and year-over-year; a 31% decrease in operating expenses, marking eight consecutive quarters of improvement based on successful cost-cutting initiatives; and $6.9 million in cash and cash equivalents with stockholder equity totaling $6.3 million.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults), plans to release its second quarter 2024 financial results after market close today, Wednesday, August 14, 2024. In addition, the company’s management will host a conference at 5 p.m. ET to review the results and provide an overview of Vivos’ recent achievements and developments. Interested participants can dial (800) 717-1738 (local) or (646) 307-1865 (international) and use the passcode 1157721. A live webcast of the call can be accessed on the company’s website.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting on the positive results from seven-month pilot test. The multisite marketing initiative tested the core assumptions behind Vivos’ new affiliation and medical sleep specialist marketing and distribution model. Earlier this month, the company unveiled the new marketing and distribution model designed to drive revenue through collaborations with dentists and sleep-treatment providers. The pilot, which involved seven dental offices and one ear, nose, and throat specialist office located across several states with highly diverse patient demographic profiles, provided a way to offer obstructive sleep apnea (“OSA”) patients a range of evidence-based treatments for OSA. Included in the treatment options were Vivos’ advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods. According to the announcement, results indicated that 79% (60 out of 76) newly diagnosed adult OSA patients chose Vivos’ oral appliance therapy over either continuous positive airway pressure (“CPAP”) machines or doing nothing. The report also indicated that 5% (4 out of 76) of patients declined all treatment options with 16% (12 out of 76) patients chosing to investigate CPAP as an option before making a final decision. “We are excited about the positive results of this pilot program and what the data shows about the potential for our new marketing and distribution model,” said Vivos Therapeutics chair and CEO Kirk Huntsman in the press release. “The message is clear: when Vivos teams up with medical professionals who treat OSA, and when patients are fully informed as to the health risks of untreated OSA and the full range of treatment options available in an open and transparent manner, they overwhelmingly chose Vivos’ CARE oral medical devices. As we continue to expand beyond dentists and move more directly and vertically into affiliations and collaborations with medical specialists, functional medicine doctors, and other sleep-related healthcare practitioners, we expect this to positively impact our new case starts, revenue growth and gross profit.”

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults). The company today announced the execution of a strategic marketing and distribution alliance with an operator of multiple sleep testing and treatment centers in Colorado. Hoped to be the first in a series across the country, the alliance marks an important pivot in Vivos’ marketing and distribution model for its cutting edge OSA appliances. “We cannot overstate the importance of this alliance to Vivos and its future, coupled with a validating private equity-led investment from Seneca,” said Kirk Huntsman, chairman and CEO of Vivos. “Over the last several years, peer-reviewed studies have confirmed our longstanding belief that Vivos has the most effective, safe and potentially lasting non-surgical solution for all severities of OSA in adults that does not require lifelong nightly intervention. This was further validated by recent unprecedented FDA clearances Vivos has received, including the only FDA clearance for an oral medical device to treat severe OSA in adults.”

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting financial results and operating highlights for the first quarter 2024, the period ended March 31, 2024. Highlights of the report include Q1 2024 revenue reaching $3.4 million; gross profit totaling $1.9 million; gross margin of 57%; a 22% decrease in operating expenses; and cash and cash equivalents totaling $2.6 million at the end of the quarter. The report noted that cost-cutting initiatives led to a significant year-over-year reduction in operating loss and an outstanding common stock purchase warrant held by an institutional investor was exercised for gross proceeds of approximately $4.0 million. In addition, last month the company received all required regulatory approvals to enable Medicare reimbursement for its CARE oral devices. “We are proud of the prudent way we have managed our costs and our cash resources as well as our successful efforts to expand our product offerings, gain unprecedented regulatory approvals and obtain Medicare reimbursement for our CARE oral devices,” said Vivos chair and CEO Kirk Huntsman in the press release. “That said, we recognize that our revenues have not grown as we would have liked. To that end, we are announcing today the anticipated launch of a new strategic revenue initiative based on collaborations to better align our interests with referring medical professionals, which we expect to materially broaden the number of OSA patients who have access to our products, make our revenue less reliant on VIP enrollments and build on the initiatives we’ve been implementing over the past year. We look forward to providing some additional details . . . in the coming weeks. All of these initiatives are intended to increase our ability to take advantage of what we see as steadily improving market conditions in OSA and open Vivos up for greater revenue opportunities. By doing this, we expect to position Vivos for long-term, sustainable revenue growth and ultimate profitability.”

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults). The company today announced plans to release its first quarter 2024 financial results after market close on Tuesday, May 14, 2024. On this same day, the company will conduct a conference call at 5:00 p.m. Eastern Time to review the results and provide an overview of its recent milestones and developments. To access Vivos’ investor conference call, dial (800) 717-1738 or (646) 307-1865 (international callers). A replay and live and archived webcast of the conference call will be available as detailed in the announcement.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is spotlighted in a recent Proactive interview. During the interview, Vivos CEO Kirk Huntsman and Proactive host Steve Darling discuss the latest news from the company, which is the regulatory approval for Medicare reimbursement of oral medical devices designed for sleep apnea treatment. Huntsman explains the unique design of the company’s medical devices, which enhance the human airway and have the potential to eliminate sleep apnea symptoms after up to 12 months of treatment. Huntsman also notes that Vivos offers the only line of oral medical devices that has received FDA approval for the treatment of obstructive sleep apnea (“OSA”). This is a significant achievement because some tens of millions of Medicare patients who suffer from OSA stand to benefit from the Vivos devices. “This recognition by the Centers for Medicare and Medicaid Services (‘CMS’) propels Vivos’s devices as a viable alternative to traditional CPAP treatments, especially timely given the recent recalls in the CPAP market and Philips’ withdrawal from the U.S. market,” the press release states. “Huntsman expressed his excitement about the broader implications of this approval, including increased recommendations of Vivos’s treatments by medical and dental providers and a growing awareness of their efficacy as an alternative to CPAP treatments. This development represents a significant step forward in transforming patient care for individuals suffering from sleep apnea.”

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, has obtained all required regulatory approvals so that its CARE oral medical devices can be reimbursed by Medicare. Calling this a “milestone achievement,” the company noted that millions of Medicare beneficiaries can now use and be reimbursed for allowable charges billable to Medicare. According to the announcement, an estimated 66.9 million people are enrolled in Medicare, and many of these beneficiaries may suffer from obstructive sleep apnea (“OSA”). “Prior to these latest developments, moderate to severe OSA patients on Medicare were relegated almost entirely to a lifetime of some form of CPAP — something most patients find undesirable,” said Vivos Therapeutics CEO and chair Kirk Huntsman in the press release. “Our CARE oral medical devices, on the other hand, can significantly improve and even resolve OSA in about 12 months, with no further intervention required in most cases. We are very pleased the Centers for Medicare and Medicaid Services (‘CMS’) recognizes and validates the benefits our FDA-cleared devices can have on the lives of patients diagnosed with OSA. Now these novel and patented devices, which have been proven effective for all levels of OSA severity in adults from mild to severe, can be accessible to more people with less out-of-pocket cost. We believe this latest regulatory approval represents an inflection point for our devices and will open the door for more OSA patients who have Medicare or commercial medical insurance coverage to receive treatment from Vivos-trained professionals utilizing our proprietary core technology and treatment protocols. This should also drive increased patient count and utilization of our Vivos devices and method.”

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults). The company today announced it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, March 28, 2024. In addition, at 5 p.m. ET on March 28, the company will conduct a conference call to review the results and provide an overview of Vivos’ recent milestones and developments. Interested parties should dial (888) 886-7786 or (416) 764-8658 (international) and enter passcode 27185528 to access the call. A replay and live and archived webcast of the conference call will be available as detailed in the announcement.

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”)). The company today announced its entry into a definitive agreement for the immediate exercise of an outstanding common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of common stock for gross proceeds to Vivos of approximately $4.0 million. As part of the transaction, the investor agreed to exercise the existing warrant (originally issued in November 2023 with an exercise price of $3.83 per share) at a revised exercise price of $4.02 per share. The resale of the shares of common stock issuable upon exercise of the warrant were registered per an effective registration statement on Form S-1. In consideration for the immediate exercise of the existing warrant for cash, Vivos agreed to issue to the investor two new unregistered warrants, each to purchase 735,296 shares of common stock (or an aggregate of 1,470,592 shares) at an exercise price of $5.05 per share. The new warrants will be exercisable immediately upon issuance. Such warrants are identical, with exception of one warrant having a term of five years and the second a term of eighteen months. A.G.P./Alliance Global Partners is acting as the exclusive financial advisor in connection with the offering.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (“OSA”) in adult patients, was spotlighted in a recent Proactive interview. During the interview, Vivos Therapeutics CEO Kirk Huntsman talked with Proactive host Steve Darling about favorable market developments that have created new opportunities for Vivos to increase its pool of potential users of Vivos’ oral appliance therapies. Specifically, Huntsman noted the FDA granted a clearance for the first time ever to an appliance designed to treat moderate and severe OSA in adults with positive airway pressure and/or myofunctional therapy. He also noted other factors contributing to the positive market conditions for Vivos, including the recent discontinuation of many Philips Respironics devices and the recalls of continuous positive airway pressure (“CPAP”) devices. Huntsman observed that these factors have created a significant opportunity for Vivos to expand its user base and offer effective treatment options to those in need.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (“OSA”) in adult patients, has noted significant favorable market developments resulting in opportunities for the company to reach out to more potential users of its oral appliance therapies. According to the company, those key developments include the U.S. Food and Drug Administration (“FDA”) granting a 510(k) clearance to the Vivos CARE appliances to treat moderate and severe OSA in adults; the recall of some Continuous Positive Airway Pressure (“CPAP”) devices as well as product shortages; the announcement by Philips Respironics that it is has suspended U.S. sales of its CPAP and other respiratory units; and United Healthcare’s revised OSA medical treatment policy requiring all OSA patients who are candidates for hypoglossal nerve stimulation (“HGNS”) implants to first complete a full regimen of oral appliance therapy.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (“OSA”), has seen significant positive numbers since it received FDA 5109k) clearance of its CARE oral medical devices. The approval was the first time the FDA has granted clearance for an oral appliance for the treatment of moderate and severe OSA in adults, 18 years of age and older along with positive airway pressure (“PAP”) and/or myofunctional therapy, as needed. According to the announcement, new-dentist inquiries have jumped an estimated 600% and signed dentist enrollment contracts have increased 38% sequentially over Q3 2023. In addition, orders for VVOS CARE oral medical device have increased 26%. The announcement also noted the success of Toothpillow, one of VIVOS’ dental service organization (“DSO”) distribution partners. The announcement noted that Toothpillow saw an all-time record month in December, with new-patient inquiries increasing by an impressive 1,500%. “Since announcing our new FDA clearance for severe OSA, we’ve seen a substantial increase in calls and inquiries from medical doctors, dentists and patients regarding Vivos’ products,” said Vivos CEO and chair Kirk Huntsman in the press release. “We believe this significant uptick in business development and revenue-generating activity since achieving this important milestone highlights our overall value proposition across both the dental and medical communities as a highly effective treatment alternative for OSA patients. With this strong momentum coming into 2024, we expect these higher inquiries and expanded sales pipeline could create opportunities for revenue growth in 2024. Not only are we experiencing considerable growth and interest related to our Vivos CARE products that treat OSA in adults, during the past few weeks we have also seen a 53% increase in sales of our pediatric-guided growth and development appliances, which we call Vivos Guides. We expect this trend to continue in the near-term, especially considering the recent success of one of our key strategic dental service organization distribution partners, Toothpillow.”

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is hosting a groundbreaking event for women in the medical and dental fields. The company announced that it is hosting a conference titled “Empowering Women to Champion Airway.” Scheduled for Feb. 1–2, 2024, the innovative event is designed to unite prominent women in key spaces as they work to spearhead positive transformations in the healthcare landscape through a focus on airway health; the event will be held at the Vivos Institute in Denver, Colorado. “We are honored to host such an all-star lineup of world-renowned speakers with expertise in a variety of healthcare specialties — including medical sleep specialists, cardiologists, primary care physicians, pediatric specialists, orthodontists and general dentists — all of whom work in one way or another with sleep and breathing disorders,” said Vivos executive vice president Susie McCullough in the press release. “Fostering this type of interdisciplinary collaboration is necessary to increase the awareness that there is a new alternative to CPAP or surgery for treating severe OSA. Not only are today’s women assuming an ever-increasing level of prominence and leadership roles within healthcare, but women continue to exert the greatest influence over family healthcare decisions. As spouses, mothers and caregivers, we are often on the front lines of dealing with the effects of OSA, snoring, insomnia, and other breathing and sleep problems. We need to know what we’re dealing with and the latest remedies that are available, with a particular emphasis on ensuring the well-being of young patients through early intervention. Vivos is proud to host this first-of-its-kind event, offering a special opportunity to glean insights into how women can drive innovation and progress in this critical facet of healthcare.”

Vivos Therapeutics experienced a rare 'black swan' event, surging over 1000% in a single day following breaking news, here's how to look at VVOS stock now

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is featured in a recent Proactive Investors interview. According to the announcement, Vivos Therapeutics CEO Kirk Huntsman joined Proactive host Steve Darling to discuss a “milestone” moment for the company: the 510(k) clearance from the U.S Food and Drug Administration (“FDA”) for the treatment of severe obstructive sleep apnea (“OSA”) in adults using Vivos’ removable CARE oral appliances. The FDA approval includes Vivos’s flagship DNA oral appliance along with its mRNA and mmRNA oral appliances. During the interview, Huntsman noted that Vivos is now the first company to receive FDA approval and bring to market a treatment for patients with severe OSA that is an alternative to continuous positive airway pressure (“CPAP”) therapy or surgical neurostimulation implants. “The operative and most important word there is severe sleep apnea,” said Vivos Therapeutics CEO Kirk Huntsman during the interview. “This is a clearance by the FDA for doctors who use our devices to treat severe apnea. Other oral appliances, including our own, have had clearances for the FDA for years to treat mild to moderate sleep apnea. But as every sleep specialist will tell you, in most patients, the greatest amount of damage is done when it gets to a severe state. So patients are at greater risk for all the comorbidities that go along with sleep apnea. The hypertension, the stroke, the Alzheimer’s — all the various comorbidities of sleep apnea are made worse when you get to the severe level. And it cuts life expectancy down by as much as 10 years. So to be able to treat, and to have the clearance to treat, severe sleep apnea with our oral appliance technology is absolutely a breakthrough. I would venture to say that since the advent of CPAP, there hasn’t been a more important regulatory clearance than the one we announced this morning.”

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, has been granted 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for treating severe obstructive sleep apnea (“OSA”) in adults using the exclusive Vivos removable Complete Airway Repositioning and/or Expansion (“CARE”) oral appliances. According to the announcement, CARE appliances include Vivos’s flagship DNA oral appliance as well as its mRNA oral appliance and mmRNA oral appliance. This clearance makes Vivos the first company to have approved and brought to market a clear alternative treatment to CPAP or surgical neurostimulation implants for patients with severe OSA. The company noted that the clearance from the FDA came only 11 months after the agency granted Vivos 510(k) clearance for the DNA oral appliance to treat mild-to-moderate OSA.

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, is reporting financial results and operating highlights for the third-quarter and nine-month period ending Sept. 30, 2023. Highlights of the report include revenue of $3.3 million for the quarter and $10.6 million for the nine-month period, compared to $4.2 million and $12.1 million for the three and nine months ended September 30, 2022, respectively; gross profit of $1.9 million for Q3 2023 and $6.3 million for the nine-month period; and gross margin came in at 57% for the third quarter of 2023, compared to 59% during the prior year period, and 60% for the 2023 nine-month period compared to 63% for the same period in 2022. The company reported decreased operating expenses and cost-cutting initiatives that contributed to significant year-over-year reductions of net loss. Operationally, the company reported that an estimated 40,000 patients have been treated with the Vivos Method with more than 1,850 dentists being trained in the use of the method; two key strategic agreements had been made, one with Ormco, a division of Envista Holdings Corporation, and one with On Demand Orthodontist (“ODO”); and an amended national distribution agreement with Lincare, which gives the leading supplier of in-home respiratory therapy products and services a six-month exclusivity period to distribute certain designated Vivos devices.

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, has closed its previously announced private placement. According to the announcement, the placement will result in approximately $3.5 million net proceeds for the company after offering expenses are deducted; the company anticipates using the funds from the placement for general working capital. According to the announcement, the transaction involved Vivos issuing 980,393 shares of its common stock (or prefunded warrants in lieu thereof) to a single institutional investor. The shares were offered at a purchase price of $4.08 per share. Vivos also issued a five-year Series A warrant and an 18-month Series B warrant to the same investor. The Series A warrant is to purchase up to 980,393 shares of common stock and the Series B Warrant is for the purchase of up to 980,393 shares of common stock. Both warrants have an exercise price of $3.83 per share and are exercisable immediately. Alliance Global Partners (“AGP”) acted as the sole placement agent for the offering.

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company has announced its entry into a securities purchase agreement with an institutional investor for the purchase and sale of 980,393 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.08 per share in a private placement priced at-the-market for purposes of Nasdaq rules. In addition, Vivos will issue to the investor a five year Series A Warrant to purchase up to an aggregate of 980,393 shares of common stock and an eighteen (18) month Series B Warrant to purchase up to an aggregate of 980,393 shares of common stock. The Series A and Series B Warrants will have an exercise price of $3.83 per share and will be exercisable immediately following the date of issuance. Subject to the satisfaction of customary conditions, the closing of the private placement is expected to occur on or about Nov. 2, 2023. Gross proceeds from the offering are expected to be approximately $4.0 million, of which Vivos intends to use the net proceeds for general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.